Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients

被引:32
作者
Akizawa, T
Suzuki, M
Akiba, T
Nishizawa, Y
Kurokawa, K
机构
[1] Wakayama Med Univ, Ctr Bloo Purificat Therapy, Wakayama 6410012, Japan
[2] Shinrakuen Hosp, Dept Internal Med, Niigata Social Serv Org, Social Welf Dept, Niigata, Japan
[3] Tokyo Womens Med Univ, Dept Blood Purificat, Kidney Ctr, Tokyo, Japan
[4] Osaka City Univ, Sch Med, Dept Internal Med 2, Osaka 545, Japan
[5] Tokai Univ, Sch Med, Isehara, Kanagawa 25911, Japan
关键词
maxacalcitol (OCT); 22-oxacalcitriol (OCT); parathyroid hormone (PTH); secondary hyperparathyroidism; uremia;
D O I
10.1053/ajkd.2001.27425
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Maxacalcitol (22-oxacalcitriol [OCT]) is a newly developed vitamin D analogue in Japan. OCT has shown less calcemic action and a strong suppressive effect on parathyroid hormone (PTH) in uremic rats and dogs. In uremic patients with secondary hyperparathyroidism, OCT dose-dependently suppressed PTH secretion and increased serum calcium levels. However, more than 60% of patients achieved a greater than 30% decrease in intact PTH level from baseline with long-term OCT treatment up to 1 year without an unphysiological increase in mean serum calcium levels. Long-term treatment also brought about a reduction in bone metabolic markers, including bone alkaline phosphatase, tartrate-resistant acid phosphatase, and bone gra-protein. These results suggest that although careful attention should be paid to the onset of hypercalcemia and oversuppression of PTH, OCT is one of the effective tools for the treatment of secondary hyperparathyroidism. (C) 2001 by the National Kidney Foundation, Inc.
引用
收藏
页码:S147 / S151
页数:5
相关论文
共 14 条
  • [1] ABE J, 1990, J NUTR SCI VITAMINOL, V36, P21, DOI 10.3177/jnsv.36.21
  • [2] Akizawa T., 1996, Journal of the American Society of Nephrology, V7, P1810
  • [3] THE NONCALCEMIC ANALOG OF VITAMIN-D, 22-OXACALCITRIOL, SUPPRESSES PARATHYROID-HORMONE SYNTHESIS AND SECRETION
    BROWN, AJ
    RITTER, CR
    FINCH, JL
    MORRISSEY, J
    MARTIN, KJ
    MURAYAMA, E
    NISHII, Y
    SLATOPOLSKY, E
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (03) : 728 - 732
  • [4] 1,25-dihydroxyvitamin D-3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats
    Denda, M
    Finch, J
    Brown, AJ
    Nishii, Y
    Kubodera, N
    Slatopolsky, E
    [J]. KIDNEY INTERNATIONAL, 1996, 50 (01) : 34 - 39
  • [5] REGULATION OF PARATHYROID-HORMONE SYNTHESIS IN CHRONIC-RENAL-FAILURE IN RATS
    FUKAGAWA, M
    KANAME, SY
    IGARASHI, T
    OGATA, E
    KUROKAWA, K
    [J]. KIDNEY INTERNATIONAL, 1991, 39 (05) : 874 - 881
  • [6] Attenuated up-regulation of vitamin D-dependent calcium-binding proteins by 22-oxa-1,25-dihydroxyvitamin D3 in uremic rats:: A possible mechanism for less-calcemic action
    Ichikawa, F
    Hirata, M
    Endo, K
    Katsumata, K
    Ohkawa, H
    Kubodera, N
    Fukagawa, M
    Kurokawa, K
    [J]. NEPHROLOGY, 1998, 4 (5-6) : 391 - 395
  • [7] *JAP SOC DIAL THER, 2001, JAP SOC DIAL THER OV
  • [8] KUBODERA N, 1992, CHEM PHARM BULL, V40, P1494
  • [9] EFFECT OF 22-OXA-CALCITRIOL ON CALCIUM-METABOLISM IN RATS WITH SEVERE SECONDARY HYPERPARATHYROIDISM
    KUBRUSLY, M
    GAGNE, ER
    URENA, P
    HANROTEL, C
    CHABANIS, S
    LACOUR, B
    DRUEKE, TB
    JEHENNE, G
    DUCHAMBON, P
    BANIDE, H
    PACHER, N
    [J]. KIDNEY INTERNATIONAL, 1993, 44 (03) : 551 - 556
  • [10] KUROKAWA K, 1999, KIDNEY DIAL, V47, P715